Haruyasu Yamaguchi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Haruyasu Yamaguchi has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
Akira Ogawa
Department of Pathology, Gunma Cancer Center, Gunma, Japan
2 shared publicationsShiro Sugihara
Department of Pathology, Gunma Cancer Center, Gunma, Japan
2 shared publicationsTakaomi C. Saido
Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan
2 shared publicationsAkihiko Takashima
Mitsubishi Kasei Institute of Life Sciences, 11 Minamiooya, Machida-shi, Tokyo 194, Japan Fax: 81-427-29-1252 JP
1 shared publicationAnn M. Saunders
Joseph and Kathleen Bryan Alzheimer's Disease Research Center, Duke University Medical Center, Durham, North Carolina, USA
1 shared publicationCynthia A. Lemere
Center for Neurologic Diseases, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, USA US
1 shared publication
Latest Publications
- 23 March 1998
- Published by Springer Nature in Acta Neuropathologica
- Vol. 95 (3) , 217-222
Diffuse plaques associated with astroglial amyloid β protein, possibly showing a disappearing stage of senile plaques
To clarify whether senile plaques disappear, we examined amyloid β protein (Aβ) deposits in non-demented subjects, and found novel diffuse plaques associated with astroglial Aβ. Formalin-fixed paraffin-embedded sections from cortical areas were immunolabeled with a panel of Aβ antibodies, and astroglial and microglial markers. Cerebral Aβ deposition was primarily found as diffuse plaques (DP) in these subjects. A subset of DP was associated with clusters of intensely Aβ-positive small granules. The clusters, which were located just adjacent to astroglial nucleus, had the characteristics of lipofuscin granules and, therefore, were quite different from “small stellate deposits”. Substantial amounts of Aβ-positive granules were found inside astrocytes by dual labeling of Aβ and glial fibrillary acid protein, and the majority of astroglial Aβ immunoreactivity was located on lipofuscin granules. Aβ-positive granules lacked immunoreactivity with antisera for the N-terminal region of Aβ. These peculiar DP showed a much weaker staining than ordinary DP. The DP associated with astroglial Aβ were found in about one third of the subjects, although the density varied widely among individuals. From these findings, we propose that DP, which are associated with the N-terminal truncated Aβ in astrocytes, represent the disappearing stage of senile plaques.
- 23 March 1998
- Published by Springer Nature in Acta Neuropathologica
- Vol. 95 (3) , 217-222
Diffuse plaques associated with astroglial amyloid β protein, possibly showing a disappearing stage of senile plaques
To clarify whether senile plaques disappear, we examined amyloid β protein (Aβ) deposits in non-demented subjects, and found novel diffuse plaques associated with astroglial Aβ. Formalin-fixed paraffin-embedded sections from cortical areas were immunolabeled with a panel of Aβ antibodies, and astroglial and microglial markers. Cerebral Aβ deposition was primarily found as diffuse plaques (DP) in these subjects. A subset of DP was associated with clusters of intensely Aβ-positive small granules. The clusters, which were located just adjacent to astroglial nucleus, had the characteristics of lipofuscin granules and, therefore, were quite different from “small stellate deposits”. Substantial amounts of Aβ-positive granules were found inside astrocytes by dual labeling of Aβ and glial fibrillary acid protein, and the majority of astroglial Aβ immunoreactivity was located on lipofuscin granules. Aβ-positive granules lacked immunoreactivity with antisera for the N-terminal region of Aβ. These peculiar DP showed a much weaker staining than ordinary DP. The DP associated with astroglial Aβ were found in about one third of the subjects, although the density varied widely among individuals. From these findings, we propose that DP, which are associated with the N-terminal truncated Aβ in astrocytes, represent the disappearing stage of senile plaques.
- 1 December 1997
- Published by Wiley in Neuropathology
- Vol. 17 (4) , 326-333
Characteristics of cerebral ? amyloid deposition in four non-demented patients in their forties with a high apolipoprotein E ?4 allele frequency
- 1 December 1997
- Published by Wiley in Neuropathology
- Vol. 17 (4) , 326-333
Characteristics of cerebral ? amyloid deposition in four non-demented patients in their forties with a high apolipoprotein E ?4 allele frequency
- 12 August 1996
- Published by Springer Nature in Acta Neuropathologica
- Vol. 92 (3) , 232-241
Preferential labeling of Alzheimer neurofibrillary tangles with antisera for tau protein kinase (TPK) I/glycogen synthase kinase-3β and cyclin-dependent kinase 5, a component of TPK II
Using immunohistochemistry, we examined the localization of four types of proline-directed kinases in the brains of control rats and in the brains of non-demented aged human subjects, subjects with Alzheimer’s disease and those with Down’s syndrome. The four kinases were: cyclin-dependent kinase (cdk) 5, a component of tau protein kinase (TPK) II; TPK I/glycogen synthase kinase (GSK)-3β; GSK-3α; and mitogen-activated protein kinase (MAPK/ERK2). Each of these kinases has been reported to promote the hyperphosphorylation of tau protein in vitro. The kinases were located essentially in neurons, although the intensity and distribution of labeling varied. Antiserum for cdk5 showed the most preferential and consistent labeling of intraneuronal neurofibrillary tangles (NFT). Antiserum for TPK I/GSK-3β also labeled intraneuronal NFT. Double immunolabeling for TPK I/GSK-3β and tau1 showed that TPK I/GSK-3β was closely associated with NFT. Antiserum for GSK-3α labeled neurons weakly, and the intensity of labeling did not differ between neurons with and without NFT. Antiserum for MAPK labeled neurons in superficial cortical layers, but NFT appeared in both superficial and deep cortical layers. These findings suggest that cdk5 and TPK I/GSK-3β are the critically important kinases for the generation in vivo of hyperphosphorylated tau, the main component of the paired helical filaments in NFT.
- 12 August 1996
- Published by Springer Nature in Acta Neuropathologica
- Vol. 92 (3) , 232-241
Preferential labeling of Alzheimer neurofibrillary tangles with antisera for tau protein kinase (TPK) I/glycogen synthase kinase-3β and cyclin-dependent kinase 5, a component of TPK II
Using immunohistochemistry, we examined the localization of four types of proline-directed kinases in the brains of control rats and in the brains of non-demented aged human subjects, subjects with Alzheimer’s disease and those with Down’s syndrome. The four kinases were: cyclin-dependent kinase (cdk) 5, a component of tau protein kinase (TPK) II; TPK I/glycogen synthase kinase (GSK)-3β; GSK-3α; and mitogen-activated protein kinase (MAPK/ERK2). Each of these kinases has been reported to promote the hyperphosphorylation of tau protein in vitro. The kinases were located essentially in neurons, although the intensity and distribution of labeling varied. Antiserum for cdk5 showed the most preferential and consistent labeling of intraneuronal neurofibrillary tangles (NFT). Antiserum for TPK I/GSK-3β also labeled intraneuronal NFT. Double immunolabeling for TPK I/GSK-3β and tau1 showed that TPK I/GSK-3β was closely associated with NFT. Antiserum for GSK-3α labeled neurons weakly, and the intensity of labeling did not differ between neurons with and without NFT. Antiserum for MAPK labeled neurons in superficial cortical layers, but NFT appeared in both superficial and deep cortical layers. These findings suggest that cdk5 and TPK I/GSK-3β are the critically important kinases for the generation in vivo of hyperphosphorylated tau, the main component of the paired helical filaments in NFT.